SavedAdd your journal

Journals / Erciyes Medical Journal / 2019 / Cilt: 41 - Sayı: 3

Rhino–Orbito–Cerebral Mucormycosis Resistant to Amphotericin B: Two Diabetic Cases

Esma EREN
Ayşegül ULU KILIÇ
Mustafa Altay ATALAY
Sare Merve BAŞAĞA
Nedret KOÇ
Emine ALP
Pages
337–340
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Diagnosis and treatment of infection are difficult.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Mucormycosis is a rare, life-threatening opportunistic infection caused by Mucorales.
📊
Key Findings & Data:The most common organisms that cause mucormycosis in humans are Rhizopus, Mucor, Rhizomucor, Lichtheimia (Absidia), and Cunninghamella.
💡
Conclusion & Impact:Diagnosis and treatment of infection are difficult.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Mucormycosis is a rare, life-threatening opportunistic infection caused by Mucorales. The most common organisms that cause mucormycosis in humans are Rhizopus, Mucor, Rhizomucor, Lichtheimia (Absidia), and Cunninghamella. Risk factors for the disease include diabetes mellitus, metabolic acidosis, hematologic malignancies, prolonged severe neutropenia, use of corticosteroids, and human immunodeficiency virus infection. Diagnosis and treatment of infection are difficult.

🔖

Cite This Article

EREN, E., KILIÇ, A. U., ATALAY, M. A., BAŞAĞA, S. M., KOÇ, N., ALP, E. (2019). Rhino–Orbito–Cerebral Mucormycosis Resistant to Amphotericin B: Two Diabetic Cases. Erciyes Medical Journal, Cilt: 41 - Sayı: 3, 337–340. https://ajindex.com/articles/223466

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options. Ann Pharmacother 2016; 50(9): 747–57. [CrossRef] Rai S, Yadav S, Kumar D, Kumar V, Rattan V. Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients. J Oral Biol Craniofac Res 2016; 6(Suppl 1): S5–S8. [CrossRef] http://blast.ncbi.nlm.nih.gov/Blast.cgi. Accessed Jul 25, 2019. Document M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard–second edition. Wayne, PA: CLSI; 2008.
  2. Lamoth F, Alexander BD. Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds. J Clin Microbiol 2015; 53(10): 3176–81. [CrossRef] Kosmidis C, Denning D.W. Opportunistic and Systemic Fungi. Cohen J, Powderly WG, Opal SM, editors. Infectious Disease; 2017. p. 1696–8. [CrossRef] Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102(3): 433–44. [CrossRef] Dannaoui E. Antifungal resistance in mucorales. Int J Antimicrob Agents 2017; 50(5): 617–21. [CrossRef] Faria-Ramos I, Farinha S, Neves-Maia J, Tavares PR, Miranda IM, Estevinho LM, et al. Development of cross-resistance by Aspergillus fumigatus to clinical azoles following exposure to prochloraz, an agricultural azole. BMC Microbiol 2014; 14: 155. [CrossRef] Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 1997; 400(1): 80–2. [CrossRef] Joseph-Horne T, Hollomon D, Loeffler RS, Kelly SL. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 1995; 39(7): 1526–9. [CrossRef] Al-Hatmi AM, Meis JF, de Hoog GS. Fusarium: Molecular Diversity and Intrinsic Drug Resistance. PLoS Pathog 2016; 12(4): e1005464. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, et al. Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis 2012;54 Suppl 1: S73–8. [CrossRef] Barnert J, Behr W, Reich H. An amphotericin B-resistant case of rhinocerebral mucor mycosis. Infection 1985; 13(3): 134–6. [CrossRef] Vyzantiadis TA, Ki